Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2014 Dec 19:11:55-8.
eCollection 2015 Jan-Apr.

A Prospective Screening of HLA-B*57.01 Allelic Variant for Preventing the Hypersensivity Reaction to Abacavir: Experience from the Laboratory of Molecular Biology of the Infectious Diseases Division at the University Hospital of Salerno

C Senatore, B Charlier, A Truono, R Punzi, F D'Aniello, N Boffa, V Izzo, V Conti, G Russomanno, V Manzo, A Filippelli, M Mazzeo

A Prospective Screening of HLA-B*57.01 Allelic Variant for Preventing the Hypersensivity Reaction to Abacavir: Experience from the Laboratory of Molecular Biology of the Infectious Diseases Division at the University Hospital of Salerno

C Senatore et al. Transl Med UniSa. .

Abstract

Abacavir is a nucleoside reverse transcriptase inhibitor largely used as part of the antiretroviral therapy in Human Immunodeficiency Virus (HIV)-infected patients. Some individuals (2-9%) who start an abacavir treatment show an immunologic reaction indicated as hypersensitivity reaction syndrome (HSR) that is often responsible for therapy discontinuation and could represent a life-threatening event. Some studies demonstrated a correlation between this adverse reaction and the class I of the major histocompatibility complex (MHC) allele, HLA-B*57.01, in several populations, including Caucasians. Nowadays, International HIV treatment guidelines recommend the HLA-B*57.01 genotyping before abacavir administration to reduce the incidence of HSR. Both male and female HIV-infected patients were enrolled at the Infectious Diseases Division at the University Hospital of Salerno, and admitted to a prospective HLAB*57.01 screening. Genetic analysis was carried out through two sequential Real-Time PCR reactions in which Sybr-Green was used. Out of 248 patients, 215 were Italians from Southern Italy and 33 were coming from several non-EU members countries. All were genotyped: 6 Italians (2.8%) and 1 of the non-EU group (3%) were identified as HLAB*57.01 carriers. In this paper we present our experience in the field of abacavir pharmacogenetic and confirm the importance of Real Time PCR as a valid and cost-effective HLA-B*57.01 typing methodology.

Keywords: Abacavir; HIV; HLA-B*57.01; Real-Time PCR; hypersensitivity reaction.

PubMed Disclaimer

Figures

Figure 1
Figure 1
amplification plots (panels A and C) and the corresponding melting curve (panels B and D)
See this image and copyright information in PMC

References

    1. Guidelines for the Use of Antiretroviral Agents in HIV infection. [Internet]. Available from: http://aidsinfo.nih.gov/guidelines.
    1. Chaponda Mas, Pirmohamed Munir. Hypersensitivity reactions to HIV therapy. Br J ClinPharmacol. 2011;71(5):659–671. - PMC - PubMed
    1. Phillips E, Malla S. Pharmacogenetics of drug hypersensitivity. Pharmacogenomics. 2010;11(7):973–987. - PMC - PubMed
    1. Hetherington S, Hughes AR, Mosteller M, et al. Genetic variations in HLA-B region and hypersensitivity reactions to abacavir. Lancet. 2002;359(9312):1121–2. - PubMed
    1. Mallal S, Nolan D, Witt C, et al. Association between presence of HLA-B*5701, HLA-DR7, and HLA-DQ3 and hypersensitivity to HIV-1 reverse-transcriptase inhibitor abacavir. Lancet. 2002;359(9308):727–32. - PubMed

LinkOut - more resources